ClinicalTrials.gg
CompletedNCT00002011Updated Jun 24, 2005

The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex

An interventional study of Methoxsalen in HIV Infections, sponsored by Therakos. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Primary conditionAIDS-Related ComplexRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
AIDS-Related Complex
Why
  1. The study's title name AIDS-Related Complex, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Therakos · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 275 studies in AIDS-Related Complex with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. AIDS-Related Complex · United States.

No phase
80 of 275
none open now
Registered
1st of 275
by date

Among the 275 studies in AIDS-Related Complex with a site in United States, this one is one of 80 with no phase, and was the 1st registered.

AIDS-Related Complex

283 studies on the registry are indexed under AIDS-Related Complex; 2 are open to participants now.

Browse AIDS-Related Complex studies →

Open to participants now

2 of the 275 studies in AIDS-Related Complex with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 AIDS-Related Complex studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in AIDS-Related Complex with a site in United States, or all of them as a file.
02

Study summary

To determine the safety and patient tolerance of UVAR Photopheresis System (extracorporeal photopheresis) in the Treatment of AIDS-Related Complex (ARC).

Read the detailed description

Treatment involves the patient ingesting 8-methoxsalen (8-MOP) by mouth approximately two hours prior to each photopheresis session. The photopheresis instrument will separate the patient's white blood cells and some plasma from other blood components and return the majority of blood components to the patient. The separated white blood cells and plasma will be exposed to UVA (Ultraviolet A) light while outside the body. The UVA light photoactivates the 8-MOP drug which is now located in the DNA of the collected cells. After this exposure, the patients photoactivated white blood cells will be returned to the patient by venous access.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • PUVA Therapy
  • Methoxsalen
  • AIDS-Related Complex
04

In context

AIDS-Related Complex Reclassified

283 studies on the registry are indexed under AIDS-Related Complex; 2 are open to participants now.

Browse AIDS-Related Complex studies →

Lead sponsor

This is the only study on the registry with Therakos as lead sponsor.

Compared within AIDS-Related Complex, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have the following:

  • Diagnosis of AIDS-related complex (ARC).
  • Veins that can provide adequate access.
  • Negative drug screen for drugs of abuse and zidovudine (AZT).
  • Be willing to adhere to the protocol and sign a patient prior to study entry.
  • Live within adequate commuting distance to the treatment center.
  • Not be on any other drug/device.
  • Be 18 - 80 years old but minimum age requirements may be affected by state regulations or specific medical conditions.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
  • Photosensitive disease, such as porphyria or systemic lupus erythematosus. Care must be taken in selecting patients who require drugs (either systemically or topically) during the course of the study with photosensitizing potential such as phenothiazines, tetracyclines, sulfonamides or chlorothiazide.
  • Renal insufficiency with creatinine > 3 mg/dl.
  • Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
  • Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
  • Idiosyncratic or reactions to 8-MOP compounds.
  • History of or active Pneumocystis carinii pneumonia, other opportunistic infection or neoplasms (Kaposi's sarcoma), or wasting syndrome.
  • Active hepatitis.
  • Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.

Concurrent Medication:

Excluded:

  • Zidovudine (AZT).
  • Photosensitizing drugs should not be administered prior to photopheresis treatment.
  • Other drugs.

Concurrent Treatment:

Excluded:

  • Other treatment using an investigational device.

Patients with the following are excluded:

  • Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
  • Photosensitive disease.
  • Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
  • Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
  • Idiosyncratic or hypersensitivity reactions to 8-MOP compounds.
  • Actively involved in drug abuse.
  • Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.

Prior Medication:

Excluded:

  • Zidovudine (AZT).

Actively involved in drug abuse.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
None (open label)

Interventions

07

Study locations

1 site
  • Morristown Memorial Hosp
    Morristown, New Jersey 07962, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002011
Lead sponsor
Therakos
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 1990. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion